文献速递神经核医学肿瘤 PET/CT

FDG PET在帕金森病及伴痴呆的非典型帕金森综合征中的临床效用

Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-05-19

本文针对FDG PET在三个临床场景中的应用进行文献检索与质量评价,并采用德尔菲法由七位专家投票。共筛选91项研究,仅4项对FDG PET性能进行了充分的定量评估。专家组基于非定量证据推荐FDG PET用于全部三个临床场景。

要点

  • 专家组推荐FDG PET用于特发性帕金森病未来认知下降风险评估。
  • 专家组推荐FDG PET用于鉴别特发性帕金森病与进行性核上性麻痹。
  • 专家组推荐FDG PET用于识别皮质基底节综合征的潜在神经病理。

核心结论

  • 尽管FDG PET在临床实践中广泛使用且研究众多,但支持其使用的优质证据仍非常有限。
  • 多数专家组成员认为FDG PET是特发性帕金森病及伴痴呆的非典型帕金森综合征的临床有用影像生物标志物。

研究设计与样本

  • 针对三个临床场景分别进行文献检索,并评价所选研究的设计质量、偏倚风险、不一致性、不精确性、间接性和效应量。
  • 由七位专家组成的小组采用德尔菲法,基于已发表证据和专家意见对FDG PET的使用进行投票。

主要发现

  • 从三次文献检索中筛选出91项研究,仅4项对FDG PET的性能进行了充分的定量评估。
  • 多数研究缺乏稳健的方法学,原因包括缺乏关键结局、金标准不充分以及未与适当参考标准进行头对头比较。
  • 专家组基于FDG PET临床效用的非定量证据,推荐其用于全部三个临床场景。

关键数值与推荐

  • 关键结局为FDG PET检测目标疾病的敏感度、特异度、准确率、阳性/阴性预测值、受试者工作特征曲线下面积及阳性/阴性似然比。
  • 专家组基于非定量证据推荐FDG PET用于全部三个临床场景:特发性帕金森病未来认知下降风险评估、鉴别特发性帕金森病与进行性核上性麻痹、识别皮质基底节综合征的潜在神经病理。

临床怎么用

  • 专家组推荐FDG PET用于特发性帕金森病未来认知下降风险评估、鉴别特发性帕金森病与进行性核上性麻痹、识别皮质基底节综合征的潜在神经病理。

局限性

  • 从三次文献检索中筛选出的91项研究中仅4项对FDG PET性能进行了充分的定量评估。
  • 多数研究缺乏稳健的方法学,原因包括缺乏关键结局、金标准不充分以及未与适当参考标准进行头对头比较。
  • 尽管FDG PET广泛使用且研究众多,但支持其使用的优质证据仍非常有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome. METHODS: We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET based on published evidence and expert opinion. RESULTS: Of 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET for all three clinical scenarios based on nonquantitative evidence of clinical utility. CONCLUSION: Despite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Walker Z, Gandolfo F, Orini S, et al. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018. PMID: 29779045. doi:10.1007/s00259-018-4031-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。